Division of Medical Oncology, University of Southern California, Norris Comprehensive Cancer Center, Keck School of Medicine, 1441 Eastlake Avenue, Los Angeles, CA 90033, USA.
Oncologist. 2010;15(8):836-44. doi: 10.1634/theoncologist.2010-0052. Epub 2010 Jul 23.
Peritoneal carcinomatosis has been considered a terminal disease with a median survival time of 5.2-12.6 months. Systemic chemotherapy and cytoreductive surgery (CRS) have long been used to treat macroscopic disease, with limited success. However, a comprehensive treatment approach involving cytroreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) has evolved into a novel approach for peritoneal carcinomatosis. Surgery removes the primary cancer and any dissemination within the peritoneal cavity and adjuvant HIPEC eradicates macroscopic or microscopic tumor residue, thus reducing the risk for recurrence. This approach offers a new potential treatment option for patients with metastatic disease confined to the peritoneum. The present review provides an update of the most recent data on the current therapy for pseudomyxoma peritonei (PMP) and mucinous colorectal adenocarcinoma (MCA) with metastatic disease confined to the peritoneum.
腹膜癌病被认为是一种终末期疾病，中位生存时间为 5.2-12.6 个月。全身化疗和细胞减灭术（CRS）长期以来一直用于治疗宏观疾病，但效果有限。然而，包括细胞减灭术和腹腔内热灌注化疗（HIPEC）在内的综合治疗方法已演变为腹膜癌病的一种新方法。手术切除原发癌症和腹腔内任何播散，辅助 HIPEC 根除宏观或微观肿瘤残留，从而降低复发风险。对于局限于腹膜的转移性疾病患者，这种方法提供了一种新的潜在治疗选择。本文综述了最近关于局限于腹膜的假性黏液瘤（PMP）和黏液性结直肠癌（MCA）伴转移性疾病的当前治疗的最新数据。
